Gasdermin D

Overview

Gasdermin D (GSDMD; Wikidata: Q21119012) is a pore-forming effector protein and the principal executioner of pyroptosis, a form of lytic, inflammatory programmed cell death. It belongs to the gasdermin superfamily, which includes closely related paralogs such as Gasdermin E (GSDME). GSDMD is composed of an N-terminal pore-forming domain and a C-terminal autoinhibitory domain held together by a linker region. Upon proteolytic cleavage — primarily by the inflammatory caspases CASP1 (caspase-1) and caspase-4/5/11 downstream of the NLRP3 inflammasome, or by caspase-8 in non-canonical pathways — the liberated N-terminal fragment (GSDMD-N) oligomerizes and inserts into the inner leaflet of the plasma membrane, forming large (~20 nm) transmembrane pores. These pores facilitate the unconventional secretion of mature pro-inflammatory cytokines, notably Interleukin 1 beta (IL-1β) and IL18, and ultimately drive osmotic cell swelling and membrane rupture, releasing damage-associated molecular patterns including High Mobility Group Box 1 (HMGB1). Beyond its canonical role in innate immunity and infection defense, GSDMD has emerged as a central node in the pathogenesis of a wide range of diseases — including metabolic disorders, fibrotic conditions, autoimmune diseases, ischemia-reperfusion injury, and cancer — making it an intensively studied therapeutic target.

GSDMD activation is tightly integrated within multiple inflammatory signaling networks. The TLR4/myeloid differentiation factor 88 (MyD88)/nuclear factor-κB (NF-κB) pathway can prime NLRP3 inflammasome assembly, coupling upstream pattern-recognition signaling to downstream GSDMD cleavage. In cancer biology, granzyme-mediated pathways (GZMA/GZMB) from cytotoxic lymphocytes and natural killer (NK) cells have been shown to cleave GSDMD directly in tumor cells, triggering pyroptosis and amplifying anti-tumor immunity. The protein's dual capacity to orchestrate inflammation and cell death positions it as both a driver of tissue pathology and a potential ally in immunogenic cancer therapy.

Focus of Latest Publications

Metabolic and Liver Disease

A 2026 study published in the Journal of Cellular and Molecular Medicine (PMID: 42219549) investigated the role of Tumour necrosis factor alpha (TNF-α) in diabetic liver injury. The research demonstrated that under high-glucose conditions, TNF-α promotes pyroptosis through the HMGB1/TLR4/MyD88/NF-κB signaling axis, with GSDMD and caspase-1 expression serving as key readouts of pyroptotic activation. Pharmacological or genetic inhibition of TNF-α attenuated GSDMD expression and downstream pyroptotic signaling, establishing a mechanistic link between diabetic hyperglycemia, inflammatory cytokine signaling, and GSDMD-driven hepatocyte death. Separately, an epigenetic study (Clinical Epigenetics, PMID: 42210364) examining predictive biomarkers of successful weight-loss intervention in pre-pubertal children with obesity identified CpG methylation sites within the GSDMD gene locus alongside genes such as GFRA1 and NRP2. The finding situates GSDMD within epigenetically regulated pathways governing inflammation, metabolic regulation, and lipid metabolism, suggesting that pyroptotic signaling may be epigenetically modulated in the context of obesity and hyperinsulinemic type 2 diabetes.

Idiopathic Pulmonary Fibrosis

GSDMD-mediated pyroptosis has been mechanistically linked to the progression of idiopathic pulmonary fibrosis (IPF). A 2026 study in the International Journal of Pharmaceutics (PMID: 41985596) developed mucus-penetrating lipid nanoparticles — specifically DPPC/AS-modified LNP and DAS-lipid nanoparticle formulations — for pulmonary co-delivery of siGSDMD (small interfering RNA targeting GSDMD) alongside plasmid DNA encoding Serum Amyloid P (SAP). In bleomycin-induced IPF mouse models, this dual-payload strategy simultaneously suppressed GSDMD-driven pyroptosis and enhanced anti-fibrotic SAP signaling, producing complementary modulation of the fibrotic microenvironment. The study demonstrates that GSDMD silencing alone is insufficient and benefits from pairing with pro-resolving mediators, establishing a combinatorial framework for IPF nanomedicine.

Autoimmune and Inflammatory Conditions

Multiple studies have examined GSDMD as a therapeutic target in autoimmune and inflammatory diseases. In rheumatoid arthritis, a study in the FASEB Journal (PMID: 42033182) interrogated the "Tianyu" traditional Chinese medicine formulation using network pharmacology and molecular docking. Five major bioactive compounds — apigenin, isorhamnetin, kaempferol, quercetin, and salidroside — were identified as binding NLRP3, caspase-1, and GSDMD with favorable binding energies (below −5 kcal/mol), validated in a collagen-induced arthritis model. In granulomatous lobular mastitis, the Tuolitounong decoction (TLTND) was shown (Journal of Molecular Histology, PMID: 42142128) to reduce cleaved GSDMD-N, cleaved caspase-1, cleaved IL-18, and cleaved IL-1β by substantial margins in rat mammary tissue, underscoring the NLRP3/caspase-1/GSDMD axis as a shared inflammatory pathway amenable to botanical intervention.

Research on muscle atrophy (Molecular Medicine Reports, PMID: 41891981) showed that Veronicastrum sibiricum extract (VSE) suppressed NLRP3 inflammasome components — including GSDMD, cleaved-GSDMD, caspase-1, and cleaved-caspase-1 — alongside mitochondrial dysfunction, pointing to GSDMD as a convergence point of metabolic and inflammatory stress in skeletal muscle. Similarly, a study on Fuzheng Jiedu Tongluo Granule in cerebral ischemia/reperfusion injury (Molecular Neurobiology, PMID: 42113382) reported suppression of GSDMD, GSDMD-N, and upstream mediators (p-Drp1, TXNIP, NLRP3) via the middle cerebral artery occlusion/reperfusion model, further implicating GSDMD-driven pyroptosis in neuroinflammatory injury. In veterinary and agricultural research, emodin was shown (International Journal of Biological Macromolecules, PMID: 41819319) to modulate the NLRP3/GSDMD pathway and alleviate Fusobacterium necrophorum-induced pyroptosis in interdigital skin fibroblasts of dairy cows, demonstrating the cross-species conservation of this signaling axis.

Oncology and Immunotherapy

GSDMD has attracted significant interest in cancer biology, both as a target to be exploited for tumor cell killing and as a component of immune effector mechanisms. A 2026 study in EMBO Molecular Medicine (PMID: 41998137) described a dual-targeted cancer vaccine (neoantigen + shared MICB α3 antigen) that mobilized innate lymphoid cell 1s (ILC1s) with high GZMA/GZMB expression to accumulate within tumors. These cytotoxic cells were found to induce Gasdermin D cleavage in tumor cells, initiating pyroptosis and triggering a cascade of cancer-immunity cycle events, including enhanced antigen presentation and synergy with checkpoint inhibitor pathways and Programmed Death-Ligand 1 (PD-L1) signaling. This mechanistic insight positions GSDMD as a bridge between cytotoxic lymphocyte function and immunogenic tumor cell death.

Two reviews and a nanomedicine study highlighted the caspase/gasdermin axes as programmable switches for cancer therapy. A Biomaterials review (PMID: 41490685) systematically examined the molecular crosstalk between apoptosis and pyroptosis, emphasizing the regulatory roles of caspase-3/GSDME and caspase-8/GSDMD axes and their potential modulation to overcome apoptosis resistance — connecting GSDMD biology to tumor protein p53 and Malignant Disease. A Tissue & Cell study (PMID: 41655514) described pyroptosis-inducing nanomedicines that exploit controlled engagement of the caspase-1/GSDMD or caspase-3/GSDME axes to induce localized membrane disruption, cytokine release, and antigen presentation in apoptosis-resistant lung cancer preclinical models. Finally, a study in Molecular Biomedicine (PMID: 42138776) investigating PANoptosis in renal cancer stem cells found that the transcription factor ZFP148 directly activated the promoters of Gsdmd, Ripk3, Il1b, and CASP1, placing GSDMD within a broader PANoptotic gene regulatory network that integrates pyroptosis, apoptosis, and necroptosis.

Key Publications

• Jun Reversing immunotherapy resistance in cold tumors by weaponizing pyroptosis with a dual-payload nanotuner. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 42314991): "...leading to caspase-1-mediated GSDMD cleavage, thereby amplifying pyroptotic cell death via the canonical pathway."
• Jun Tumour Necrosis Factor-α Promotes Pyroptosis in Diabetic Liver Injury via the HMGB1/TLR4/MyD88/NF-κB Pathway. (Journal of cellular and molecular medicine, 2026, PMID 42219549): "In vitro assessments included the expression of pyroptosis-related proteins (caspase1, Gasdermin D [GSDMD]), high mobility group protein B1 (HMGB1), and components of the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor-κB (NF-κB) pathway under high glucose conditions with or without TNF-α inhibition."
• May Predictive epigenetic biomarkers of successful weight-loss intervention in pre-pubertal children with obesity. (Clinical epigenetics, 2026, PMID 42210364): "CpGs were found in genes such as GSDMD, GFRA1 and NRP2, all linked to pathways involved in inflammation, metabolic regulation, and lipid metabolism, which are crucial in the development of obesity."
• May Mucus-penetrating lipid nanoparticles overcome lung barriers for pulmonary co-delivery of siGSDMD and pDNA-SAP in idiopathic pulmonary fibrosis. (International journal of pharmaceutics, 2026, PMID 41985596): "Pyroptosis mediated by gasdermin D (GSDMD) has been linked to disease advancement by releasing pro-fibrotic mediators."
• May Therapeutic effects of Tuolitounong decoction on pyroptosis in granulomatous lobular mastitis: evidence from in vitro and in vivo models. (Journal of molecular histology, 2026, PMID 42142128): "Of note, TLTND significantly reduced the protein expression levels of key pyroptosis markers (cleaved caspase-1, n-GSDMD, cleaved IL-18 and cleaved IL-1β) by 52.6%, 91.0%, 78.1% and 87.1%, respectively, compared to the model group in rat mammary tissue."
• May Superparamagnetic iron oxide nanoparticle-driven 3-aroyl-1,4-diarylpyrrole nanocomposites (ARDAP@SPION-PEI) mediate renal cancer cell PANoptosis by regulating chromatin accessibility. (Molecular biomedicine, 2026, PMID 42138776): "Luciferase reporter assays demonstrated that ZFP148 directly bound to and activated promoters of key PANoptosis-related genes, including receptor-interacting serine/threonine kinase 3 (Ripk3), gasdermin D (Gsdmd), IL-1β (Il1b), and caspase-1 (Casp1)."
• May The "Tianyu" Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42033182): "...molecular docking showed that all five major compounds (Apigenin, Isorhamnetin, Kaempferol, Quercetin, and Salidroside) bound well to NLRP3, Caspase-1, and GSDMD, with all binding energies below -5 kcal/mol."
• May Fuzheng Jiedu Tongluo Granule Alleviates Cerebral Ischemia/reperfusion Injury-induced Inflammation By Inhibiting Drp1-mediated TXNIP/NLRP3 Pathway. (Molecular neurobiology, 2026, PMID 42113382): "as evidenced by the suppression of mRNA and protein expression of p-Drp1, TXNIP, NLRP3, GSDMD, GSDMD-N, Caspase-1, Cleaved caspase-1, and ASC."
• Apr Neoantigens and shared MICB α3 antigen dual-targeted vaccine generates potent antitumor immunity. (EMBO molecular medicine, 2026, PMID 41998137): "which can induce Gasdermin D cleavage in tumor cells to initiate tumor pyroptosis for a cascade of cancer-immunity cycle."
• Apr Harnessing the death switch: Empowering cancer therapy by modulating the apoptosis-pyroptosis transition. (Biomaterials, 2026, PMID 41490685): "This review systematically examines the intricate molecular crosstalk between cell death modalities, with particular emphasis on the regulatory roles of the caspase-3/GSDME and caspase-8/GSDMD axes."